DUBLIN – 2017 marks the year that the connection between European biotech and Nasdaq solidified into what now looks to be an unbreakable bond. As of Dec. 22, European biotechs engaged in drug development raised a record $2.75 billion in IPOs and follow-on offerings on the U.S. exchange, dwarfing the previous record total of $1.79 billion raised in 2015. European firms raised $949 million in eight IPOs and another $1.8 billion in 16 secondary offerings in the past year.